Adimab Collaborations for Biospecific Antibody Discovery
Collaborations and development goes hand in hand in progressive biotech industries. U.S. based Adimab has been a seasoned player in this field. Adimab– a global leader in discovery and optimization of fully human monoclonal and biospecific antibodies collaborated with iTeos Therapeutics and Kodiak Sciences under two independent partnerships. Eli Lilly and Company, Kite Pharma and Jounce Therapeutics also secured independent commercial licences to antibody programs generated under existing partnerships.
iTeos Therapeutics and Kodiak Sciences will get the licence to utilize the proprietary platform of Adimab to optimize antibodies against particular targets independently. They will also gain the right for the development and commercialization of the therapeutic antibodies which will be generated as an outcome of collaboration.
Since Adimab’s inception in 2007, it has generated a wide spectrum of funded discovery collaborations with over 35 companies. The collaborations included some of the big renowned names of biotech sector like Eli Lilly, Novo Nordisk, Biogen, GSK, Roche, Novartis, Genentech, Celgene, Gilead, Sanofi, Takeda and many others. Other than these Adimab has also partnered with many mid-size, early-stage venture-backed companies as well as academic institutions.
“About three years ago we started partnering with early stage companies that were pursuing very innovative and novel disease biology,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “These partnerships have been quite successful. Our partners can immediately leverage our industry-leading discovery capabilities at a relative cost. This allows our partners to focus on the underlying biology for their programs and rapidly develop a pre-clinical pipeline.”
“We are pleased with the success of our collaboration with Adimab. The versatility and quality of the Adimab platform have been instrumental in supporting our CAR-T cell therapies beyond KTE-C19,” said Tony Polverino, Ph.D., Vice President, Research of Kite Pharma. “We look forward to continuing our partnership with Adimab to advance important therapies for cancer patients.”
Just few days back, Adimab and Japan based Takeda signed a multi-target collaborative deal to discover and develop bispecific antibodies against multiple targets.
According to the agreement;
- Adimab shall use its proprietary yeast based optimisation and discovery platform for the identification of fully human antibodies against selected targets. It may also use its rapid B cell sorting platform.
- For each selected target, Takeda shall be granted the rights to research any antibodies that are generated during the collaboration for potential use in therapeutic products.
- For each target, Takeda shall have an option of exclusively licensing the generated antibodies for which Adimab shall receive license fees, clinical milestones and royalties on product sales.
The financial details of the deal however remain an undisclosed suspense.
“We are pleased to be working with a company with such deep expertise in antibody discovery and engineering,” stated Christopher Claiborne, Ph.D., Head of Oncology Discovery at Takeda.
Few months ago Adimab exploited its single B cell isolation platform in a pro bono project aimed at reducing the amount of time taken to identify a lineup of antibodies that could be used to combat Ebola.
Featured Image credit: Plasma cell B lymphocyte producing antibodies isolated on black © exty (BigStock Photo ID: 91024310)